



A biologically-based mathematical model for prediction of metastatic relapse

Michalis Mastri, Cynthia Perier, Gaetan Macgrogan, John M.L. Ebos,
Sébastien Benzekry

► To cite this version:

Michalis Mastri, Cynthia Perier, Gaetan Macgrogan, John M.L. Ebos, Sébastien Benzekry. A biologically-based mathematical model for prediction of metastatic relapse. 17th Biennial Congress of the Metastasis Research Society, Aug 2018, Princeton, United States. hal-01968980

HAL Id: hal-01968980

<https://inria.hal.science/hal-01968980>

Submitted on 3 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A biologically-based mathematical model for prediction of metastatic relapse

M. Mastri¹

C. Périer²

G. MacGrogan³

J. ML Ebos¹

S. Benzekry²

¹Department of Cancer Genetics and Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA

²Inria team MONC and Institut de Mathématiques de Bordeaux, Talence, France


³Pathology department, Institut Bergonié, Centre de Recherche et de Lutte Contre le Cancer, Bordeaux, France

BACKGROUND & OBJECTIVES


- Metastasis is the cause of **90% of deaths** from solid tumors *Chaffer and Weinberg, Science 2011*
- ~20-30% of breast cancer patients will relapse with distant metastases *EBCTG, Lancet, 2005*
- For breast cancer, the current factors influencing decision for **adjuvant therapy** are: tumor size, nodal involvement, molecular factors (hormonal receptors and HER2 status), histological type and grade.

Objective: establish a biologically-based mathematical model for individualised prediction of metastasis

Breast cancer data base (1057 patients), I. Bergonié



AN ELEMENTARY THEORY OF METASTATIC DYNAMICS: GROWTH + DISSEMINATION



Growth rates of primary and secondary tumors

$$g_p \text{ and } g \quad \frac{dV_p}{dt} = g_p(V_p(t))$$

Poisson process for the dissemination with rate

$$d(V_p) = \mu V_p \gamma$$

Size distribution of the metastases $\rho(t, v)$

Iwata et al., J Theor Biol, 2000

$$\begin{cases} \partial_t \rho(t, v) + \partial_v (g(v) \rho(t, v)) = 0 \\ g(V_0) \rho(t, V_0) = d(V_p(t)) \\ \rho(0, v) = \rho^0 \end{cases}$$

Number of visible metastases


$$N_{vis}(t) = \int_0^{t-\tau_{vis}} d(V_p(t)) \mathbb{1}_{V_p(t) \leq V_d} dt$$

Time to relapse


$$TTR = \inf \{t > 0; N_{vis}(t) > 1\}$$

Total metastatic mass


$$M(t) = \int_{V_0}^{+\infty} v \rho(t, v) dv = \int_0^t d(V_p(t-s)) V(s) ds$$



PRECLINICAL DATA AND POPULATION APPROACH



- * Data primary tumor
- Median model primary tumor
- - 10th and 90th percentiles model primary tumor
- o Data metastatic burden
- Median model metastatic burden
- - 10th and 90th percentiles model metastatic burden



$$M_j^i = M(t_j^i, \theta^i) + \sigma(M(t_j^i, \theta^i)) \varepsilon_j^i, \quad \varepsilon_j^i \sim \mathcal{N}(0, 1)$$

Structural model

Error model


Individual parameter θ^i

$$\theta^i = \theta_{pop} + \beta^T x^i + \eta_i$$

$$\eta_i \sim \mathcal{N}(0, \omega^2)$$

Population fits

(nonlinear mixed-effects)



CLINICAL DATA OF METASTATIC RELAPSE PROBABILITY

2648 breast cancer patients screened for 20 years after primary tumor resection (no adjuvant therapy)

Koscielny et al., Br J Cancer, 1984


Cancer inception time can be inferred from PT volume V_1 at diagnosis time T_1 (Gompertz growth).

Lognormal distribution of **metastatic parameter μ** for inter-individual variability (2 degrees of freedom)

$$\mathbb{P}(\text{Mets}) = \mathbb{P}\left(\mu \int_0^{T_1} V_p(t) dt > 1\right)$$

Diameter of primary tumor at diagnosis (cm)	Proportion of patients developing metastasis (%)	Model fit
$1 \leq D \leq 2.5$	27.1	25.5
$2.5 < D \leq 3.5$	42.0	42.4
$3.5 < D \leq 4.5$	56.7	56.3
$4.5 < D \leq 5.5$	66.5	65.9
$5.5 < D \leq 6.5$	72.8	74.3
$6.5 < D \leq 7.5$	83.8	80.8
$7.5 < D \leq 8.5$	81.3	85.7


PERSONALIZED SIMULATIONS FOR DIAGNOSIS AND PROGNOSIS OF BRAIN METASTASES IN LUNG CANCER



PREDICTIVE PERFORMANCES FOR 5-YEARS METASTATIC RELAPSE FROM BREAST

	AUROC	Accuracy	NPV	PPV
Random forest	0.727	87	91.7	22.5
Logistic regression	0.772	90.1	91	25
Cox regression	0.728	87.4	91.1	16.7
Bio-based	0.641	89.7	91.3	31.2

AUROC = Area Under the ROC curve, NPV = Negative Predictive Value
PPV = Positive Predictive Value



	p
tumor_size_clinical	0.00165
tumor_size_histological	0.4
grade	0.358
histology	0.0041
TNM.T	0.146
TNM.N	0.599
nb_invaded_ganglions	0.619
menopausal_status	0.000471
ER	0.543
PR	0.34
Ki67	3.09e-05
HER2	0.17
HER2_intensity	0.482
CK56	0.793
EGFR	0.016
VIM	0.226
ALDH1	0.674
CD24	0.894
CD44	0.397
E_cadherin	0.207
TRIO	0.0646
BCL2	0.727
age_at_diagnosis	0.0599
diagnosis_year	0.101
radio	0.276

Features selection based on Cox regression

CONCLUSION AND FUTURE DIRECTIONS

- A **biologically-based** mathematical model was able to **describe preclinical and clinical data** of metastatic development in breast, lung and kidney cancer
 - Machine learning algorithms used here don't account for censored data + limited to prediction of relapse event at a fixed horizon
 - The biological model accounts for these and could give predictions of the metastatic state at diagnosis and future evolution in order to **guide therapeutic intervention**
 - Predictive power is **only modest so far** but only the primary tumor size was considered here as a feature with only other source of inter-subject variability being the dissemination parameter μ
- ==> include **more features** and link parameter μ and others to clinical features and biomarkers in a **biologically relevant way**